Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (121-130 of 350) with videos related to

Pageof 35
Sort By:
Journal of Crohn'S & Colitis|September 10, 2015
Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's DiseaseMagali de Bruyn, Ingrid Arijs, Gert De Hertogh, et al.
Inflammatory Bowel Diseases|October 4, 2023
Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn's Disease: A Prospective Monocentric StudyGabriele Bislenghi, Julie Van Den Bossch, Steffen Fieuws, et al.
Clinical and Translational Gastroenterology|December 9, 2016
Rapid Test for Infliximab Drug Concentration Allows Immediate Dose AdaptationThomas Van Stappen, Lize Bollen, Niels Vande Casteele, et al.
Journal of Crohn'S & Colitis|May 9, 2022
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative ColitisDahham Alsoud, Gert De Hertogh, Griet Compernolle, et al.
Inflammatory Bowel Diseases|October 25, 2019
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral CenterMichiel Bronswijk, Annick Moens, Matthias Lenfant, et al.
Journal of Crohn'S & Colitis|October 18, 2018
Vedolizumab in Refractory Microscopic Colitis: An International Case SeriesPauline Rivière, Andreas Münch, Pierre Michetti, et al.
Inflammatory Bowel Diseases|December 25, 2024
Dietary Carrageenan Amplifies the Inflammatory Profile, but not Permeability, of Intestinal Epithelial Cells from Patients With Crohn's DiseaseEva Vissers, Judith Wellens, Lorenzo Giorio, et al.
Inflammatory Bowel Diseases|January 12, 2024
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort StudyDahham Alsoud, João Sabino, Denis Franchimont, et al.
Inflammatory Bowel Diseases|November 16, 2017
Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over TimeSumin Bian, Erwin Dreesen, Ho Tsun Tang, et al.
Crohn'S & Colitis 360|July 11, 2025
Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn's Disease: Results From the EVOLVE Expansion StudyBritt Christensen, Michael Scharl, Brian Bressler, et al.
Pageof 35

Showing results (121-130 of 350) with videos related to

Sort By:
Pageof 35
Journal of Crohn'S & Colitis|September 10, 2015
Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's DiseaseMagali de Bruyn, Ingrid Arijs, Gert De Hertogh, et al.
Inflammatory Bowel Diseases|October 4, 2023
Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn's Disease: A Prospective Monocentric StudyGabriele Bislenghi, Julie Van Den Bossch, Steffen Fieuws, et al.
Clinical and Translational Gastroenterology|December 9, 2016
Rapid Test for Infliximab Drug Concentration Allows Immediate Dose AdaptationThomas Van Stappen, Lize Bollen, Niels Vande Casteele, et al.
Journal of Crohn'S & Colitis|May 9, 2022
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative ColitisDahham Alsoud, Gert De Hertogh, Griet Compernolle, et al.
Inflammatory Bowel Diseases|October 25, 2019
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral CenterMichiel Bronswijk, Annick Moens, Matthias Lenfant, et al.
Journal of Crohn'S & Colitis|October 18, 2018
Vedolizumab in Refractory Microscopic Colitis: An International Case SeriesPauline Rivière, Andreas Münch, Pierre Michetti, et al.
Inflammatory Bowel Diseases|December 25, 2024
Dietary Carrageenan Amplifies the Inflammatory Profile, but not Permeability, of Intestinal Epithelial Cells from Patients With Crohn's DiseaseEva Vissers, Judith Wellens, Lorenzo Giorio, et al.
Inflammatory Bowel Diseases|January 12, 2024
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort StudyDahham Alsoud, João Sabino, Denis Franchimont, et al.
Inflammatory Bowel Diseases|November 16, 2017
Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over TimeSumin Bian, Erwin Dreesen, Ho Tsun Tang, et al.
Crohn'S & Colitis 360|July 11, 2025
Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn's Disease: Results From the EVOLVE Expansion StudyBritt Christensen, Michael Scharl, Brian Bressler, et al.
Pageof 35